Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience

Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience

Dabrafenib is a potent BRAF-kinase inhibitor. Its activity was evaluated on 40 consecutive metastatic melanoma patients (pts) harboring the V600BRAF mutations. Dabrafenib was administered orally at the dosage of 150 mg b.i.d. daily. ORR was 82%, with 7% CR, 62% PR, 13% SD and 18% PD. The median PFS...

Full description

Bibliographic Details
Main Authors: Cocorocchio, E, Gandini, S, Alfieri, S, Battaglia, A, Pennacchioli, E, Tosti, G, Spadola, G, Barberis, M, Leo, M Di, Riviello, C, Pala, L, Intelisano, A, Martinoli, C, Ferrucci, PF
Format: Online
Language:English
Published: Cancer Intelligence 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778691/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4778691/

Similar Items